Clinical trials: Overweight and/or Obesity
Overweight or Obese
Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.
- Trial name
- NCT07036601
- Testing
- THDBH120 injection
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Obesity, Overweight
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity.
- Trial name
- NCT07476118
- Testing
- Brenipatide
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background…
- Trial name
- ENLIGHTEN-6 (NCT07392190)
- Testing
- Eloralintide
- Where
- 185 sites in United States, Australia and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Healthy Participants
A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
This study will measure the effects of multiple doses of AZD6234, AZD9550 and a combination of AZD9550 and AZD6234 given as injection(s) on pharmacokinetics (PK) of combined oral contraceptive (CoC) ethinyl estradiol…
- Trial name
- NCT07013643
- Testing
- AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP)
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy, Overweight and Obese Adults
A Study of SYNT-101 to Test Safety, Tolerability and Pharmacodynamics of SYNT-101 in Healthy and Overweight Adults
A Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacodynamics of single and multiple dose regimens of SYNT-101 in healthy and overweight adults.
- Trial name
- NCT07307274
- Testing
- SYNT101
- Where
- Australia
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Syntis Bio
Overweight, Obesity
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
The study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
- Trial name
- NCT06904105
- Testing
- HRS-7535 Tablets
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight
The main objective of the study is to assess the pharmacokinetics (PK) of Maridebart Cafraglutide after a single subcutaneous (SC) administration in overweight or obese Chinese participants.
- Trial name
- NCT06352892
- Testing
- Maridebart Cafraglutide
- Where
- Hong Kong
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Amgen
Metabolism and Nutrition Disorder, Obesity
Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity
The study is testing a new medicine for weight control in people with overweight or obesity. The aim of the study is to find out how safe the study medicine is and how it works in the body.
- Trial name
- NCT03661879
- Testing
- NNC9204-1706
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Alcohol Use Disorder (AUD)
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight.
- Trial name
- NCT06987513
- Testing
- Pemvidutide
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Altimmune, Inc.
Obesity
Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children
The purpose of this clinical trial is to examine the effects of conjugated linoleic acid (CLA) vs metformin along with an intervention program with healthy habits on body composition, weight, M value in CLAMP and clinical…
- Trial name
- NCT02063802
- Testing
- metformin, Conjugated Linoleic Acid, Healthy habits program
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Overweight or Obesity
A Study of TG103 Injection in Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase II study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of two dose levels of TG103 injection, a GLP-1…
- Trial name
- NCT05299697
- Testing
- TG103 15 mg, TG103 22.5 mg
- Where
- China
- Volunteers
- 195 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity & Overweight
BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity.
- Trial name
- NCT07622810
- Testing
- Bofanglutida, Semaglutide
- Where
- 6 sites in Mexico
- Volunteers
- 352 people
- Sponsor
- Carnot Laboratories
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Obesity
A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06567327
- Testing
- Danuglipron, Atorvastatin, Rosuvastatin
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity &Amp; Overweight
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite…
- Trial name
- NCT07056842
- Testing
- Rifampin + VCT220, Itraconazole + VCT220
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Overweight, Obesity
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide.
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- RENEW 2 (NCT07220759)
- Testing
- Cagrilintide
- Where
- 67 sites in United States, Argentina and 9 more
- Volunteers
- 330 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
- Trial name
- NCT06047548
- Testing
- Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 441 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of once-weekly HRS-4729 injection in adults with obesity without diabetes.
- Trial name
- NCT07690826
- Testing
- HRS-4729 Injection, HRS-4729 Injection;
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity or Overweight, Type 2 Diabetes Mellitus
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith2 (NCT07351058)
- Testing
- Enicepatide
- Where
- 210 sites in United States, Argentina and 19 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Obesity
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.
- Trial name
- NCT06893016
- Testing
- RAY1225
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd